Explore. Learn. Join the conversation.

Working Group on New TB Drugs

Stop TB Partnership

Dr. Iwao Ojima

TB R&D Update: Podcast Interview with Dr. Iwao Ojima

Dr. Iwao Ojima is a Distinguished Professor and Director of the Institute of Chemical Biology and Drug Discovery at Stony Brook University. In this interview, Dr. Ojima discusses the work his lab has been doing on tri-substituted benzimidazole compou...

Listing to Podcast

View All Podcasts »

exposed

UPDATE Exposed: Aeras’ Film Series on Tuberculosis

Release of Chapter 1 of EXPOSED occured the week of May 20. EXPOSED is a four-part series of short films that tell the story of the deadly global epidemic of tuberculosis. The series will portray the struggles of four inspiring individuals - an MDR...

Watch Video

View All Videos »

MSF video

Multidrug-Resistance Tuberculosis: No Promises

A video from Medecins Sans Frontieres entitled "Multidrug-Resistance Tuberculosis: No Promises" on the situation of children affected with MDR-TB. It highlights the dire plight of children being treated for MDR-TB in Tajikistan....

Watch Video

View All Videos »

thumb206-andy

The Growing Landscape of TB Trials: Interview with Dr. Andrew Vernon

This week we highlight an interview with Dr. Andrew Vernon, the Chief, Clinical Research Branch, Division of Tuberculosis Elimination at the U.S. Centers for Disease Control and Prevention (CDC). He discusses the progress made in TB drug developmen...

Watch Video

View All Videos »

previous next

Messages to our members

WGND Annual Meeting, Oct. 29th

This meeting will be  held before the 45th Union World Conference on Lung Health on October 29th, from 15:00 to 19:00. Register by sending an email to Private Email.

View All Messages »

From the blog

TAG

2014 Report on Tuberculosis Research Funding Trends, 2005–2013

Worldwide, governments, foundations, and companies invested US$676.7 million in research to develop new drugs, vaccines, and diagnostics against tuberculosis (TB) in 2013—barely one-third of the US$2 billion that experts estimate the world must spend each year to end the global TB epidemic—according to an analysis released today by Treatment Action Group (TAG).

Posted 24 October 2014 | No Comments

Get involved

Site features

Global Discovery Programs

An online tool that invites developers to submit their discovery programs so we can provide a more complete snapshot of current global efforts.

View Pipeline

The Global TB Drugs Pipeline

An online tool that invites developers to submit their TB drug candidates so we can provide a more complete snapshot of current global efforts.

View Pipeline

TB Resources Database

A growing collection of resources to help access Tools, Knowledge, Facilities, and People in the TB drug development R&D community.

View TB Resources

Why We Need New TB Drugs

Today's TB drug regimen takes too long to be effective and requires too many medications. Treatment of drug-sensitive disease requires 6-9 months whereas treatment of drug-resistant TB is even lengthier, taking 18-24 months or longer.

Read More

About us

Our Mission

To accelerate the discovery and development of new drugs for the treatment of tuberculosis by bringing together the stakeholders in TB Drug Development, including the patients themselves.
Read More »

Global Members

The WGND is composed of diverse interested stakeholders in TB drug development, including those working in TB drug R&D, regulators, public health workers, funders, community representatives, advocates and policy-makers.
Read More »

Total members: 255

WGND Members:

Martin Johan Boeree

PanACEA Consortium and the Radboud University Nijmegen Medical Centre

Hiromu Kawakubo

Asahi Kasei Chemicals Corporation

Neeraj Dhar

Global Health Institute, Swiss Federal Institute of Technology Lausanne

Santiago Ramn Garca

The University of British Columbia

Kobina Bosumtwi Dadzie

wiljok Childaid and health organization

David Greeley

TB Alliance

Cherise Scott

Stop TB Partnership Working Group on New TB Drugs

Barry Furr

Astrazeneca

Martin Graham

PKPD Bioscience

Avishek Anant

National Institute of Immunology

View All Members »